Works matching 5Q deletion syndrome

Results: 128
    1
    2

    Evolution of severe (transfusion‐dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage‐associated failure of the eythropoietic niche.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 1, p. 114, doi. 10.1111/bjh.18163
    By:
    • Buesche, Guntram;
    • Teoman, Huesniye;
    • Schneider, Rebekka K.;
    • Ribezzo, Flavia;
    • Ebert, Benjamin L.;
    • Giagounidis, Aristoteles;
    • Göhring, Gudrun;
    • Schlegelberger, Brigitte;
    • Bock, Oliver;
    • Ganser, Arnold;
    • Aul, Carlo;
    • Germing, Ulrich;
    • Kreipe, Hans
    Publication type:
    Article
    3
    4
    5
    6
    7
    8

    Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

    Published in:
    European Journal of Haematology, 2010, v. 85, n. 3, p. 231, doi. 10.1111/j.1600-0609.2010.01473.x
    By:
    • Oliva, Esther N.;
    • Cuzzola, Maria;
    • Nobile, Francesco;
    • Ronco, Francesca;
    • D'Errigo, Maria Grazia;
    • Lagan, Carmelo;
    • Morabito, Fortunato;
    • Galimberti, Sara;
    • Cortelezzi, Agostino;
    • Aloe Spiriti, Maria A.;
    • Specchia, Giorgina;
    • Poloni, Antonella;
    • Breccia, Massimo;
    • Ghio, Riccardo;
    • Finelli, Carlo;
    • Iacopino, Pasquale;
    • Alimena, Giuliana;
    • Latagliata, Roberto
    Publication type:
    Article
    9
    10
    11
    12

    Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

    Published in:
    British Journal of Haematology, 2014, v. 166, n. 2, p. 189, doi. 10.1111/bjh.12876
    By:
    • Sánchez‐García, Joaquín;
    • del Cañizo, Consuelo;
    • Lorenzo, Ignacio;
    • Nomdedeu, Benet;
    • Luño, Elisa;
    • Paz, Raquel;
    • Xicoy, Blanca;
    • Valcárcel, David;
    • Brunet, Salut;
    • Marco‐Betes, Victor;
    • García‐Pintos, Marta;
    • Osorio, Santiago;
    • Tormo, Mar;
    • Bailén, Alicia;
    • Cerveró, Carlos;
    • Ramos, Fernando;
    • Diez‐Campelo, María;
    • Such, Esperanza;
    • Arrizabalaga, Beatriz;
    • Azaceta, Gemma
    Publication type:
    Article
    13

    Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

    Published in:
    2021
    By:
    • Hecht, Anna;
    • Meyer, Julia A.;
    • Jann, Johann-Christoph;
    • Sockel, Katja;
    • Giagounidis, Aristoteles;
    • Götze, Katharina S.;
    • Letsch, Anne;
    • Haase, Detlef;
    • Schlenk, Richard F.;
    • Haferlach, Torsten;
    • Schafhausen, Philippe;
    • Bug, Gesine;
    • Lübbert, Michael;
    • Thol, Felicitas;
    • Büsche, Guntram;
    • Schuler, Esther;
    • Nowak, Verena;
    • Obländer, Julia;
    • Fey, Stephanie;
    • Müller, Nadine
    Publication type:
    journal article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 6, p. E207, doi. 10.1002/ajh.26162
    By:
    • Panagiota, Victoria;
    • Meggendorfer, Manja;
    • Kubasch, Anne Sophie;
    • Gabdoulline, Razif;
    • Krönke, Jan;
    • Mies, Anna;
    • Shahswar, Rabia;
    • Kandziora, Christian;
    • Klement, Piroska;
    • Schiller, Johannes;
    • Göhring, Gudrun;
    • Haferlach, Claudia;
    • Ganster, Christina;
    • Shirneshan, Katayoon;
    • Gutermuth, Annika;
    • Thiede, Christian;
    • Germing, Ulrich;
    • Schroeder, Thomas;
    • Kobbe, Guido;
    • Klesse, Sabrina
    Publication type:
    Article
    29
    30
    31

    Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00724-3
    By:
    • Gurnari, Carmelo;
    • Piciocchi, Alfonso;
    • Soddu, Stefano;
    • Bonanni, Fabrizio;
    • Scalzulli, Emilia;
    • Niscola, Pasquale;
    • Di Veroli, Ambra;
    • Piccioni, Anna Lina;
    • Piedimonte, Monica;
    • Maiorana, Gianluca;
    • Salutari, Prassede;
    • Cicconi, Laura;
    • Santopietro, Michelina;
    • Gumenyuk, Svitlana;
    • Sarlo, Chiara;
    • Fenu, Susanna;
    • Tafuri, Agostino;
    • Latagliata, Roberto;
    • Fianchi, Luana;
    • Criscuolo, Marianna
    Publication type:
    Article
    32
    33
    34
    35

    Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

    Published in:
    Journal of Clinical Investigation, 2015, v. 125, n. 3, p. 1043, doi. 10.1172/JCI78789
    By:
    • Saunthararajah, Yogen;
    • Sekeres, Mikkael;
    • Advani, Anjali;
    • Mahfouz, Reda;
    • Durkin, Lisa;
    • Radivoyevitch, Tomas;
    • Englehaupt, Ricki;
    • Juersivich, Joy;
    • Cooper, Kathleen;
    • Husseinzadeh, Holleh;
    • Przychodzen, Bartlomiej;
    • Rump, Matthew;
    • Hobson, Sean;
    • Earl, Marc;
    • Sobecks, Ronald;
    • Dean, Robert;
    • Reu, Frederic;
    • Tiu, Ramon;
    • Hamilton, Betty;
    • Copelan, Edward
    Publication type:
    Article
    36
    37
    38

    Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.

    Published in:
    Mycoses, 2015, v. 58, n. 9, p. 565, doi. 10.1111/myc.12357
    By:
    • Cho, Sung‐Yeon;
    • Lee, Dong‐Gun;
    • Choi, Su‐Mi;
    • Choi, Jae‐Ki;
    • Lee, Hyo‐Jin;
    • Kim, Si‐Hyun;
    • Park, Sun Hee;
    • Choi, Jung‐Hyun;
    • Yoo, Jin‐Hong;
    • Kim, Yoo‐Jin;
    • Kim, Hee‐Je;
    • Min, Woo‐Sung
    Publication type:
    Article
    39
    40
    41
    42
    43
    44

    Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.

    Published in:
    Leukemia & Lymphoma, 2018, v. 59, n. 5, p. 1095, doi. 10.1080/10428194.2017.1366998
    By:
    • On behalf of Grupo Andaluz SMD;
    • Sanchez-Garcia, Joaquin;
    • Casaño, Francisco Javier;
    • Serrano, Josefina;
    • Falantes, Jose;
    • Solé Rodriguez, María;
    • Calderon, Cristina;
    • Medina Perez, Angeles;
    • Hernandez-Mohedo, Francisca;
    • Hermosin, Lourdes;
    • Torres-Sabariego, Angeles;
    • Labrador, Maria;
    • Vahí, Maria;
    • Bailen, Alicia;
    • Hernandez-Sanchez, Jesus M.;
    • Lumbreras, Eva;
    • Hernández-Rivas, Jesus Maria
    Publication type:
    Article
    45

    Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

    Published in:
    Leukemia & Lymphoma, 2013, v. 54, n. 4, p. 874, doi. 10.3109/10428194.2012.728702
    By:
    • Abouyahya, Imane;
    • Alhan, Canan;
    • Westers, Theresia M.;
    • te Boekhorst, Peter A.;
    • Kappers-Klunne, Mies C.;
    • Coenen, Jules L.;
    • Heyning, Fenna H.;
    • Huls, Gerwin A.;
    • de Wolf, Joost T.;
    • Imholz, Alex L.;
    • Koene, Harry R.;
    • Veth, Gerda;
    • de Kruijf, Evert-Jan F. M.;
    • Muus, Petra;
    • Planken, Erwin V.;
    • Segeren, Christine M.;
    • Vasmel, Wies L.;
    • van der Velden, Ankie M.;
    • Velders, Gerjo A.;
    • Koedam, Jan
    Publication type:
    Article
    46
    47
    48
    49
    50